Regenerative medical company Mesoblast
(ASX:MSB) has entered into a $75 million non-dilutive four year credit facility with Hercules Capital.
The proceeds will be used for funding the commercialization of its graft versus host disease therapies after the product successfully met its phase 3 trials primary endpoint.
The facility will also be used for the company’s late stage product candidates for chronic heart failure and chronic low back pain.
Mesoblast is a global leader in developing innovative cell based medicines and has three programs in phase 3 clinical trials.
Shares in Mesoblast are trading 0.55 per cent lower at is to $1.81.
